| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:27647594 | IVR | 250 mg/kg | 250 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations |
| IVR | 500 mg/kg | 500 mg/kg | Affects the biochemical composition of uterus | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Affects the biochemical composition of ovary | Reproductive endocrine-mediated perturbations | |
| IVR | 250 mg/kg | 250 mg/kg | Affects the biochemical composition of ovary | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations | |
| IVR | 250 mg/kg | 250 mg/kg | Affects the biochemical composition of uterus | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects the biochemical composition of ovary | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects the biochemical composition of uterus | Reproductive endocrine-mediated perturbations | |
| PMID:33358858 | IVR | 16 mg/kg | 16 mg/kg | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations |
| IVR | 16 mg/kg | 16 mg/kg | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Decreased inhibin-B levels | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Decreased Anti-Müllerian hormone (AMH) levels | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| PMID:39017946 | IVR | 16 mg/kg/day | 16 mg/kg/day | Increased body weights | Metabolic endocrine-mediated perturbations |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 13 - 16 mg/kg/day | 13 - 16 mg/kg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.